Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

CERT vs VEEV vs MEDP vs IQV vs DOCS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CERT
Certara, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$1.03B
5Y Perf.-77.7%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$27.35B
5Y Perf.-45.9%
MEDP
Medpace Holdings, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$12.24B
5Y Perf.+142.7%
IQV
IQVIA Holdings Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$30.32B
5Y Perf.-26.3%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$5.24B
5Y Perf.-55.3%

CERT vs VEEV vs MEDP vs IQV vs DOCS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CERT logoCERT
VEEV logoVEEV
MEDP logoMEDP
IQV logoIQV
DOCS logoDOCS
IndustryMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Healthcare Information Services
Market Cap$1.03B$27.35B$12.24B$30.32B$5.24B
Revenue (TTM)$419M$3.20B$2.68B$16.63B$638M
Net Income (TTM)$-2M$909M$460M$1.39B$239M
Gross Margin61.5%75.5%29.1%26.1%89.7%
Operating Margin5.0%28.7%21.0%13.9%37.4%
Forward P/E14.1x19.0x25.2x14.1x16.8x
Total Debt$11M$96M$250M$16.17B$12M
Cash & Equiv.$189M$1.42B$497M$1.98B$210M

CERT vs VEEV vs MEDP vs IQV vs DOCSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CERT
VEEV
MEDP
IQV
DOCS
StockJun 21May 26Return
Certara, Inc. (CERT)10022.3-77.7%
Veeva Systems Inc. (VEEV)10054.1-45.9%
Medpace Holdings, I… (MEDP)100242.7+142.7%
IQVIA Holdings Inc. (IQV)10073.7-26.3%
Doximity, Inc. (DOCS)10044.7-55.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: CERT vs VEEV vs MEDP vs IQV vs DOCS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MEDP and DOCS are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Doximity, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. VEEV and IQV also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
CERT
Certara, Inc.
The Value Angle

Among these 5 stocks, CERT doesn't own a clear edge in any measured category.

Best for: healthcare exposure
VEEV
Veeva Systems Inc.
The Income Pick

VEEV ranks third and is worth considering specifically for income & stability and sleep-well-at-night.

  • beta 0.77
  • Lower volatility, beta 0.77, Low D/E 1.3%, current ratio 4.89x
  • Beta 0.77, current ratio 4.89x
  • Beta 0.77 vs IQV's 1.33, lower leverage
Best for: income & stability and sleep-well-at-night
MEDP
Medpace Holdings, Inc.
The Long-Run Compounder

MEDP has the current edge in this matchup, primarily because of its strength in long-term compounding.

  • 14.4% 10Y total return vs VEEV's 5.2%
  • +42.9% vs DOCS's -55.4%
  • 24.8% ROA vs CERT's -0.1%, ROIC 154.9% vs 1.5%
Best for: long-term compounding
IQV
IQVIA Holdings Inc.
The Value Play

IQV is the clearest fit if your priority is value.

  • Lower P/E (14.1x vs 25.2x), PEG 0.35 vs 0.79
Best for: value
DOCS
Doximity, Inc.
The Growth Play

DOCS is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.

  • Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
  • PEG 0.21 vs VEEV's 1.04
  • 20.0% revenue growth vs IQV's 5.9%
  • 37.5% margin vs CERT's -0.4%
Best for: growth exposure and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthDOCS logoDOCS20.0% revenue growth vs IQV's 5.9%
ValueIQV logoIQVLower P/E (14.1x vs 25.2x), PEG 0.35 vs 0.79
Quality / MarginsDOCS logoDOCS37.5% margin vs CERT's -0.4%
Stability / SafetyVEEV logoVEEVBeta 0.77 vs IQV's 1.33, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)MEDP logoMEDP+42.9% vs DOCS's -55.4%
Efficiency (ROA)MEDP logoMEDP24.8% ROA vs CERT's -0.1%, ROIC 154.9% vs 1.5%

CERT vs VEEV vs MEDP vs IQV vs DOCS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CERTCertara, Inc.
FY 2025
Reportable Segment
100.0%$419M
VEEVVeeva Systems Inc.
FY 2025
Subscription Services Veeva Research And Development
43.0%$1.2B
Subscription Services Veeva Commercial Cloud
40.2%$1.1B
Professional Services Veeva Research And Development
10.1%$277M
Professional Services Veeva Commercial Cloud
6.7%$185M
MEDPMedpace Holdings, Inc.
FY 2025
Oncology
29.5%$748M
Metabolic
29.4%$745M
Other
16.1%$409M
Central Nervous System
10.1%$255M
Cardiology
9.5%$239M
Antiviral And Anti Infective
5.3%$135M
IQVIQVIA Holdings Inc.
FY 2025
Research And Development Solutions
54.5%$8.9B
Technology And Analytics Solutions
40.6%$6.6B
Contract Sales And Medical Solutions
4.8%$788M
DOCSDoximity, Inc.
FY 2025
Subscription
95.3%$544M
Service, Other
4.7%$27M

CERT vs VEEV vs MEDP vs IQV vs DOCS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMEDPLAGGINGIQV

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 4 of 6 comparable metrics.

IQV is the larger business by revenue, generating $16.6B annually — 39.7x CERT's $419M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to CERT's -0.4%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCERT logoCERTCertara, Inc.VEEV logoVEEVVeeva Systems Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…DOCS logoDOCSDoximity, Inc.
RevenueTrailing 12 months$419M$3.2B$2.7B$16.6B$638M
EBITDAEarnings before interest/tax$78M$956M$577M$3.5B$250M
Net IncomeAfter-tax profit-$2M$909M$460M$1.4B$239M
Free Cash FlowCash after capex$67M$1.4B$745M$2.7B$314M
Gross MarginGross profit ÷ Revenue+61.5%+75.5%+29.1%+26.1%+89.7%
Operating MarginEBIT ÷ Revenue+5.0%+28.7%+21.0%+13.9%+37.4%
Net MarginNet income ÷ Revenue-0.4%+28.4%+17.2%+8.3%+37.5%
FCF MarginFCF ÷ Revenue+15.9%+43.7%+27.8%+16.1%+49.2%
Rev. Growth (YoY)Latest quarter vs prior year+3.3%+16.0%+26.5%+8.4%+9.8%
EPS Growth (YoY)Latest quarter vs prior year-191.0%+23.9%+16.6%+15.0%-16.2%
DOCS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

CERT leads this category, winning 4 of 7 comparable metrics.

At 22.8x trailing earnings, IQV trades at a 26% valuation discount to VEEV's 30.9x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.30x vs VEEV's 1.70x — a lower PEG means you pay less per unit of expected earnings growth.

MetricCERT logoCERTCertara, Inc.VEEV logoVEEVVeeva Systems Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…DOCS logoDOCSDoximity, Inc.
Market CapShares × price$1.0B$27.4B$12.2B$30.3B$5.2B
Enterprise ValueMkt cap + debt − cash$857M$26.0B$12.0B$44.5B$5.0B
Trailing P/EPrice ÷ TTM EPS-631.00x30.92x28.06x22.79x23.45x
Forward P/EPrice ÷ next-FY EPS est.14.10x18.98x25.24x14.06x16.83x
PEG RatioP/E ÷ EPS growth rate1.70x0.88x0.56x0.30x
EV / EBITDAEnterprise value multiple11.05x28.40x21.31x12.97x21.14x
Price / SalesMarket cap ÷ Revenue2.47x8.56x4.84x1.86x9.18x
Price / BookPrice ÷ Book value/share0.95x3.89x27.57x4.67x4.84x
Price / FCFMarket cap ÷ FCF10.94x19.33x17.96x14.78x19.64x
CERT leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

MEDP leads this category, winning 4 of 8 comparable metrics.

MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $-0 for CERT. CERT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs IQV's 4/9, reflecting strong financial health.

MetricCERT logoCERTCertara, Inc.VEEV logoVEEVVeeva Systems Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…DOCS logoDOCSDoximity, Inc.
ROE (TTM)Return on equity-0.2%+13.4%+120.9%+22.1%+24.4%
ROA (TTM)Return on assets-0.1%+11.1%+24.8%+4.7%+20.7%
ROICReturn on invested capital+1.5%+12.9%+154.9%+8.7%+20.0%
ROCEReturn on capital employed+1.5%+13.8%+65.7%+11.0%+22.3%
Piotroski ScoreFundamental quality 0–966649
Debt / EquityFinancial leverage0.01x0.01x0.55x2.44x0.01x
Net DebtTotal debt minus cash-$178M-$1.3B-$247M$14.2B-$197M
Cash & Equiv.Liquid assets$189M$1.4B$497M$2.0B$210M
Total DebtShort + long-term debt$11M$96M$250M$16.2B$12M
Interest CoverageEBIT ÷ Interest expense3.10x
MEDP leads this category, winning 4 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

MEDP leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in MEDP five years ago would be worth $25,938 today (with dividends reinvested), compared to $2,141 for CERT. Over the past 12 months, MEDP leads with a +42.9% total return vs DOCS's -55.4%. The 3-year compound annual growth rate (CAGR) favors MEDP at 27.0% vs CERT's -35.4% — a key indicator of consistent wealth creation.

MetricCERT logoCERTCertara, Inc.VEEV logoVEEVVeeva Systems Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…DOCS logoDOCSDoximity, Inc.
YTD ReturnYear-to-date-27.8%-23.4%-24.9%-20.7%-39.9%
1-Year ReturnPast 12 months-44.9%-29.4%+42.9%+16.5%-55.4%
3-Year ReturnCumulative with dividends-73.1%-5.2%+104.6%-5.9%-24.2%
5-Year ReturnCumulative with dividends-78.6%-35.3%+159.4%-23.8%-50.9%
10-Year ReturnCumulative with dividends-83.4%+519.4%+1442.7%+166.5%-50.9%
CAGR (3Y)Annualised 3-year return-35.4%-1.8%+27.0%-2.0%-8.8%
MEDP leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — VEEV and IQV each lead in 1 of 2 comparable metrics.

VEEV is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 72.3% from its 52-week high vs DOCS's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCERT logoCERTCertara, Inc.VEEV logoVEEVVeeva Systems Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…DOCS logoDOCSDoximity, Inc.
Beta (5Y)Sensitivity to S&P 5001.21x0.77x1.26x1.33x1.03x
52-Week HighHighest price in past year$13.88$310.50$628.92$247.05$76.51
52-Week LowLowest price in past year$5.19$148.05$284.48$134.65$20.55
% of 52W HighCurrent price vs 52-week peak+45.5%+54.2%+68.2%+72.3%+34.0%
RSI (14)Momentum oscillator 0–10053.549.640.658.560.1
Avg Volume (50D)Average daily shares traded3.5M2.3M371K1.6M2.7M
Evenly matched — VEEV and IQV each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: CERT as "Buy", VEEV as "Buy", MEDP as "Hold", IQV as "Buy", DOCS as "Buy". Consensus price targets imply 66.5% upside for VEEV (target: $280) vs 16.4% for MEDP (target: $499).

MetricCERT logoCERTCertara, Inc.VEEV logoVEEVVeeva Systems Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…DOCS logoDOCSDoximity, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuyBuy
Price TargetConsensus 12-month target$10.00$280.10$498.86$225.63$42.79
# AnalystsCovering analysts1442194422
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+4.1%+0.6%+7.5%+4.1%+2.3%
Insufficient data to determine a leader in this category.
Key Takeaway

MEDP leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). DOCS leads in 1 (Income & Cash Flow). 1 tied.

Best OverallMedpace Holdings, Inc. (MEDP)Leads 2 of 6 categories
Loading custom metrics...

CERT vs VEEV vs MEDP vs IQV vs DOCS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CERT or VEEV or MEDP or IQV or DOCS a better buy right now?

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Certara, Inc. (CERT) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CERT or VEEV or MEDP or IQV or DOCS?

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus Veeva Systems Inc. at 30. 9x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 21x versus Veeva Systems Inc. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — CERT or VEEV or MEDP or IQV or DOCS?

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 4%, compared to -78. 6% for Certara, Inc. (CERT). Over 10 years, the gap is even starker: MEDP returned +1443% versus CERT's -83. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CERT or VEEV or MEDP or IQV or DOCS?

By beta (market sensitivity over 5 years), Veeva Systems Inc.

(VEEV) is the lower-risk stock at 0. 77β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 72% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Certara, Inc. (CERT) carries a lower debt/equity ratio of 1% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — CERT or VEEV or MEDP or IQV or DOCS?

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Certara, Inc. grew EPS 86. 7% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CERT or VEEV or MEDP or IQV or DOCS?

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -0. 4% for Certara, Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus 5. 0% for CERT. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CERT or VEEV or MEDP or IQV or DOCS more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 21x versus Veeva Systems Inc. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 1x forward P/E versus 25. 2x for Medpace Holdings, Inc. — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.

08

Which pays a better dividend — CERT or VEEV or MEDP or IQV or DOCS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is CERT or VEEV or MEDP or IQV or DOCS better for a retirement portfolio?

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Both have compounded well over 10 years (MEDP: +1443%, CERT: -83. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CERT and VEEV and MEDP and IQV and DOCS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CERT is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; MEDP is a mid-cap high-growth stock; IQV is a mid-cap quality compounder stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CERT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 36%
Run This Screen
Stocks Like

VEEV

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 17%
Run This Screen
Stocks Like

MEDP

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Net Margin > 10%
Run This Screen
Stocks Like

IQV

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

DOCS

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 22%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CERT and VEEV and MEDP and IQV and DOCS on the metrics below

Revenue Growth>
%
(CERT: 3.3% · VEEV: 16.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.